MindMed Finalizes Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication NEW YORK, May 17, 2021 /CNW/ — MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announces receipt of Type C Meeting Responses from FDA leading to the finalization of the Company’s clinical development approach for Project Lucy by…


Previous articlePsychedelic Bulletin: MAPS Study Published in Nature Medicine; Numinus’ Hiring Spree; CB Therapeutics’ Series A
Next articleRevive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip